anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides an agent delivery system comprising an agent preparation encapsulated within a membrane composition. The invention further provides a membrane composition comprising a ganglioside and lipid for encapsulating agents, and processes for preparing the membrane compositions. The invention further provides agent preparations encapsulated within the membrane compositions, including a plurality of individual particles wherein each particle contains agent preparation individually encapsulated within membrane composition. The invention also provides processes for preparing encapsulated agent preparations or individual particles of encapsulated agent preparations. The agents may be biologically active including hydrophilic, hydrophobic, small molecule or large molecule therapeutic agents. The invention further provides pharmaceutical compositions comprising encapsulated agent preparations or individual particles of encapsulated agent preparations. The invention further provides methods for delivery of the encapsulated agent preparations or individual particles of encapsulated agent preparations to a subject, including oral delivery of large molecule therapeutic agents to the lymphatic system, blood circulatory system, and/or targeted delivery to cells, tissues or organs.
Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week.
Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) increasingly added to other drugs in the treatment of colorectal cancer. Bev is typically used in combination with other chemotherapeutic agents such as oxaliplatin, irinotecan, leucovorin and 5-fluorouracil (5-FU) for treatment of patients with CRLM. The objective of this study was to assess the impact of neoadjuvant bevacizumab on clinical outcome after hepatectomy of colorectal liver metastases (CRLM).

Patients, who underwent liver resection due to colorectal liver metastases after neoadjuvant chemotherapy, operated between 2005 and 2007 will be evaluated retrospectively. The patients will be distributed in two groups, either with or without bevacicumab. Outcome parameters are mortality, complications, hospital stay and ICU stay. To increase the power of the study the total number of patients will be increased by adding patients from other centers. Results will be adjusted for the propensity of developing complications.
For the tissue adhesive, we will use Dermabond, which was FDA approved for skin closure in 1998. We will record the length of time of each closure method for comparison, and have patients follow-up at two, six and 12 weeks. At the 12 week visit we will score the appearance of the incision.
Patients will be randomized at their pre-surgical consultation. Patients will undergo a physical therapy evaluation, nutritional counseling and group therapy, prior to surgery and at 4 and 8 weeks post-op. Their preoperative visits will be as close to 4 weeks before surgery as possible but given the urgency of some of these surgeries and diagnoses, treatment will not be delayed to complete the components of this study. The patient will also be asked to complete a quality of life assessment at the beginning and end of the study as well as an anonymous survey at the conclusion of the study evaluating her satisfaction with the experiment. Patient nutritional assessments will be obtained with Patient Generated Subjective Global Assessment questionnaires as well as targeted questioning by the dietician.
After the implants were fully seated, a Smartpeg specific to the implant system and restorative platform diameter was used for each implant. RFA was then performed using an OsstellMentor device from Ostell/Integration Diagnostics in Gothenburg, Sweden. This analysis was used to measure the ISQ values for all implant surfaces at days 0, 7 and 30 post-surgeries. For each implant, 4 readings were taken per lingual, mesial, distal, and vestibular direction. The average ISQ values of all the readings were recorded. Following the RFA measurements, new sterile healing abutments were inserted, and the incisions were sutured to close the wounds.
BACKGROUND: Being able to differentiate mild cognitive impairment (MCI) patients who would eventually convert (MCIc) to Alzheimer's disease (AD) from those who would not (MCInc) is a key challenge for prognosis.
OBJECTIVE: This study aimed to investigate the ability of sulcal morphometry to predict MCI progression to AD, dedicating special attention to an accurate identification of sulci.
METHODS: Twenty-five AD patients, thirty-seven MCI and twenty-five healthy controls (HC) underwent a brain-MR protocol (1.5T scanner) including a high-resolution T1-weighted sequence. MCI patients underwent a neuropsychological assessment at baseline and were clinically re-evaluated after a mean of 2.3 years. At follow-up, 12 MCI were classified as MCInc and 25 as MCIc. Sulcal morphometry was investigated using the BrainVISA framework. Consistency of sulci across subjects was ensured by visual inspection and manual correction of the automatic labelling in each subject. Sulcal surface, depth, length, and width were retrieved from 106 sulci. Features were compared across groups and their classification accuracy in predicting MCI conversion was tested. Potential relationships between sulcal features and cognitive scores were explored using Spearman's correlation.
RESULTS: The width of sulci in the temporo-occipital region strongly differentiated between each pair of groups. Comparing MCIc and MCInc, the width of several sulci in the bilateral temporo-occipital and left frontal areas was significantly altered. Higher width of frontal sulci was associated with worse performances in short-term verbal memory and phonemic fluency.
CONCLUSIONS: Sulcal morphometry emerged as a strong tool for differentiating HC, MCI, and AD, demonstrating its potential prognostic value for the MCI population.
PURPOSE OF REVIEW: Large nonpedunculated colorectal polyps ≥ 20 mm (LNPCPs) comprise 1% of all colorectal lesions. LNPCPs are more likely to contain advanced histology such as high-grade dysplasia and submucosal invasive cancer (SMIC). Endoscopic resection is the first-line approach for management of these lesions. Endoscopic resection options include endoscopic mucosal resection (EMR), cold-snare EMR (EMR), endoscopic submucosal dissection (ESD) and endoscopic full-thickness resection (EFTR). This review aimed to critically evaluate current endoscopic resection techniques.
RECENT FINDINGS: Evidence-based selective resection algorithms should inform the most appropriate endoscopic resection technique. Most LNPCPs are removed by conventional EMR but there has been a trend toward C-EMR for endoscopic resection of LNPCPs. More high-quality trials are required to better define the limitations of C-EMR. Advances in our understanding of ESD technique, has clarified its role within the colorectum. More recently, the development of a full thickness resection device (FTRD) has allowed the curative endoscopic resection of select lesions.
SUMMARY: Endoscopic resection should be regarded as the principle approach for all LNPCPs. Underpinned by high-quality research, endoscopic resection has become more nuanced, leading to improved patient outcomes.
FIELD: cosmetology.SUBSTANCE: invention relates to the field of cosmetology, dermatology and plastic surgery. A safe puncture point for the cannula guide needle is chosen. Zones with a shortage of soft tissue volume in the area of exposure are marked, in the direction of these zones, the marking of the intended vectors of the passage of the cannula, diverging in the form of rays from a safe puncture point, is applied. In one procedure, a complete correction of all involutional changes is carried out, namely, both the lacrimal and palpebromal grooves are corrected, with additional correction of the middle third of the face. At the same time, the volume deficit in the upper buccal region is assessed in the projection of the articulation of the zygomatic and maxillary bone, relative to the skin-zygomatic ligament, and a single safe and anatomically justified cannula puncture point for working with all these structures is determined taking into account the individual characteristics of the patient’s soft tissue structure, namely, the intersection of two lines is found: a line drawn through the lacrimal groove of the patient, and a line drawn through the outer edge of the iris. The marking of the cannula direction vectors from a single safe puncture point is applied: to the lacrimal groove, to the palpebromal groove, to the medial part of the deep suborbital fat pack SOOF and to the deep medial fat pack of the cheek DMC. Preparations based on hyaluronic acid are chosen based on their rheological properties: modulus of elasticity G', rigidity, hygroscopicity, as a result, when correcting the lacrimal and palpebromal sulcus, Teosyal Puresense Redensity 2 is used, having minimal hygroscopicity, modulus of elasticity G' is 69 Pa, minimal rigidity, degree of hyaluronic acid reticulation MoD is 4.6. When correcting medial SOOF, the drug Teosyal RHA4, which has a maximum modulus of elasticity G', 263.3 Pa, minimal rigidity, degree of hyaluronic acid reticulation MoD 4.0 is used. And when correcting DMC, the drug Teosyal Puresense Ultra Deep is used, which has a maximum modulus of elasticity G', 262 Pa, and maximum rigidity, the degree of hyaluronic acid reticulation MoD is 8.9.EFFECT: method provides correction of the infraorbital area due to a differentiated approach to the selection of drugs, preserving the naturalness of the results obtained.1 cl, 1 ex, 5 dwg
DNAs encoding glutamate and avermectin-sensitive chloride channels have been cloned and characterized. The individual alpha and beta subunits are capable of forming homomeric and heteromeric channels selectively opened with either avermectin or glutamate. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified. Receptor modulators are useful as insecticides and anthelminthic agents.
One aspect of the invention is a salt comprising guanidinium groups, as shown in formula I. Another aspect of the invention is a salt comprising guanidinium groups, as shown in formula II. Another aspect of the invention is a salt comprising guanidinium groups, as shown in formula III. Another aspect of the invention is a salt comprising guanidinium groups, as shown in formula IV. Yet another aspect of the invention is a salt comprising guanidinium groups, as shown in formula I, II, III, and IV further comprising independently for each occurrence citrate, phosphate, or sulfate anion. Also disclosed are compositions comprising a protein and a salt comprising guanidinium groups, as shown in formula I, II, III, and IV. Also provided are methods of increasing shelf life of an aqueous solution of a protein and decreasing the amount of protein aggregation in an aqueous solution of a protein.
Individualize dosing and use the lowest dose of JESDUVROQ sufficient to reduce the need for red blood cell transfusions. Do not target a hemoglobin higher than 11 g/dL.

JESDUVROQ can be taken with or without food, and without regard to concomitant administration of iron or phosphate binders [see Clinical Pharmacology (12.3)].

JESDUVROQ should be swallowed whole. Tablets should not be cut, crushed, or chewed.

JESDUVROQ can be administered without regard to the timing or type of dialysis [see Clinical Pharmacology (12.3)].

If a dose of JESDUVROQ is missed, it should be taken as soon as possible, unless it is the same day as the next dose. In this case, the missed dose should be skipped, and the next dose taken at the usual time. Double-doses should not be taken to make-up for a missed dose.
SGLT-2 inhibitors such as empagliflozin inhibit the SGLT-2 transport in the proximal tubular cells of the kidney, thereby causing glucosuria to approximately 100 g per day (and sometimes even more). The SGLT-2 inhibition does not only cause glucosuria but also natriuresis, since with each molecule of glucose one molecule of sodium is inhibited to be reabsorbed. Indeed, during the first week SGLT-2 inhibition causes clinically detectable natriuresis but its effect in the long run is not yet illustrated. Of course, a new sodium balance will be achieved after a certain time (otherwise the human body would be completely salt depleted), but total sodium content could be different. With new innovative magnetic resonance imaging (MRI) technology we are able to assess tissue sodium content in the skin and muscle, and observed that sodium content is significantly increased with aging, severe hypertension or hyperaldosteronism. Furthermore, skin sodium content assessed by MRI was closely related to left ventricular mass (r=0.559, p\<0.0001, N=89) independently of age, gender, body mass index, and 24 h ambulatory blood pressure (β=0.343, p=0.001, N=89) 11. Using this technology, our first yet unpublished data (clinicaltrials.gov: NCT02383238) indicate that SGLT-2 inhibition decreases sodium content in the skin in patients with diabetes. Finally, we observed previously that in patients with acute chronic heart failure skin sodium content decreased from 43.5 mmol/l to 32.2 mmol/l after diuretic therapy.

Thus, the present study aims at analyzing changes in total and tissue sodium content after SGLT-2 inhibition with empagliflozin. In parallel, sodium intake and excretion and central systolic and pulse pressure as well as other vascular parameters will be assessed. In face of the upcoming studies with empagliflozin conducted in patients with reduced and preserved ejection fraction (two large-scale, prospective, doubleblind, placebo controlled studies planned by Boehringer Ingelheim as the sponsor), we thought that we focus on patients with chronic heart failure irrespective diabetic status. The hypothesis is that the SGLT-2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure, and if the hypothesis is proven, that this mechanism contributes to the beneficial effects found in EMPA-REG Outcome trial potentially via exerting beneficial effects on the vascular structure and function of the micro- and macrocirculation.
A cationic group-containing copolymer is provided which possesses excellent thixotropy and exhibits high adsorbability to the skin, hair, etc. and, when incorporated as a thickener in cosmetic articles, manifests a very satisfactory tactile sensation. The cationic group-containing copolymer is characterized in that the viscosity at 25 DEG C. of the aqueous solution prepared by incorporating the copolymer in deionized water at a concentration of 0.5 wt. % is in the range of 0.3-20 Paxsec. at a shear rate of 1 sec-1 and in the range of 0.01-5 Paxsec. at a shear rate of 10 sec-1 and the viscosity at a shear rate of 1 sec-1 is higher than the viscosity at a shear rate of 10 sec-1. A thickener made of the copolymer is also disclosed.
Participants in this arm will NOT have a summary of their family's psychosocial risk factors provided to the treatment team shortly after diagnosis. However, the risk factors will be distributed to the treatment team 6 months following diagnosis.
160 patients will be enrolled and randomized with a treatment arm allocation ratio of 1:1 in the Phase 2 study. At enrollment, patients will be assessed with medical history, physical/neurological examinations, standard laboratory evaluations (CBC with differential and comprehensive metabolic panel (CMP)), baseline brain MRI with and without gadolinium, cognitive testing and patient-reported outcome questionnaires of HRQoL. On the first day of BMX-001 (loading dose), patients will be evaluated with medical history, patient physical/neurological examinations, and standard laboratory evaluations (CBC with differential and CMP), and ECG. Patients in Arm A will be administered BMX-001 subcutaneously first as a loading dose before the start of chemoradiation and then at maintenance dose (50% of the loading dose) twice a week for 8 weeks. Because oxidative stress continues to occur for up to several weeks following RT, the proposed protocol includes administering BMX-001 both before the start of RT and continuing for 2 weeks after the completion of RT and TMZ. TMZ will be dosed at 75 mg/m2 orally daily for 42 days and RT will be delivered in daily fractions of 1.8-2 Gy given 5 days a week for 6 weeks for a total of 59.4-60 Gy. During standard RT and TMZ, CBC with differential and CMP will be obtained weekly. Two weeks after the completion of standard RT and TMZ and every 8 weeks during adjuvant TMZ, patients will be evaluated with the following: medical history, physical/neurological examinations, Brain MRI with and without gadolinium, cognitive testing and patient-reported outcome questionnaires of HRQoL. Two weeks after the completion of chemoradiation, patients will transition to adjuvant chemotherapy with TMZ dosed at 150-200 mg/m2 orally for 5 days of a 28-day cycle for a total of 12 cycles. In light of the findings that BMX-001 can spare radiation-induced hair loss in a mouse model \[41\], we will evaluate and describe hair loss as an exploratory outcome in HGG patients by evaluating hair at baseline and then every 8 weeks. Patients will be discontinued from the study if they experience progression of disease, death or withdraw informed consent.
The present invention relates to a novel ending blood vessel embolic agent which comprises metal cores and adhesive. The present invention is characterized in that the metal cores are connected by the adhesive to form a granular structure. Moreover, the present invention has good visibility in the X-ray and proper specific weight, and simultaneously, the embolism in the blood vessel can be easily formed. Furthermore, the back flow can not be easily formed so that the mistake embolic operation can be effectively avoided. The nuclear magnetic resonance (MRI) examination can be carried out after the embolic operation, and the present invention has the obvious advantage of low price. The present invention is an ideal material for the ending blood vessel embolism.
The present invention relates to a medicine composition for treating psoriasis and neurodermatitis. The present invention is composed by the following proportions: 1.25 to 16 portions of long-noded pit viper, and 5 to 30 portions of toosendan fruits or nims, is soaked and dissolved by alcohol or phthalate solvents, and medicine liquids are soaked out to be applied to external application. The alcohol solvents adopt ethanol, isopropanol, normal butanol or spirit, and the present invention is soaked and dissolved for more than three days in the alcohol solvents to be applied to the external application. Tripterygium wilfordii and honeysuckle respectively have the adding quantity that the tripterygium wilfordii is 10 to 100 portions and the honeysuckle is 10 to 100 portions to form a liniment type or an application type. The soaked component of the present invention can be added into water gel matrices to manufacture facial washing milk, facial masks and external application medicines. The present invention has the advantages of small toxic side effect on treating psoriasis and neurodermatitis, low cost, convenient application and simple preparation technology.
Norelgestromin/ethinyl estradiol is a contraceptive patch shown to be safe and effective for the prevention of pregnancy. The usual treatment regimen is three consecutive seven-day patches followed by one patch-free week. This cyclic method is followed in order to mimic the 28-day menstrual cycle. An extended contraceptive regimen (administration of active hormones for greater than 21 days) of oral contraceptives is a common practice among women wishing to delay or prevent withdrawal bleeding for reasons such as athletic participation or going on vacation. In addition to the convenience of reducing the frequency of withdrawal bleeds, elimination of the hormone-free interval reportedly reduces many menstrually-related symptoms (headaches, pelvic pain, breast tenderness, bloating, swelling) that occur at a greater frequency during the hormone-free interval than during the rest of the cycle. Headache is one of the most common adverse effects associated with hormonal contraceptive use. Studies have demonstrated that headaches were reduced in subjects using extended intervals of active hormone. However, one of the main side effects reported with extended regimens is breakthrough bleeding and/or spotting. Compared to cyclic regimens, extended oral contraceptive use may be associated with an increased incidence of breakthrough bleeding and spotting, especially during the first few months of use. This is a randomized (patients are assigned different treatments based on chance), open-label, multicenter study comparing the bleeding profile of norelgestromin/ethinyl estradiol patch continuous regimen to norelgestromin/ethinyl estradiol patch cyclic regimen. Safety evaluations include adverse event reporting, physical examinations, blood levels, and vital signs. The hypothesis of the study is that norelgestromin/ethinyl estradiol in an extended regimen of 84 days of active hormone would result in fewer days and episodes of bleeding compared to a traditional cyclic regimen of norelgestromin/ethinyl estradiol. Patients receive norelgestromin/ethinyl estradiol patches in a plastic sleeve. In the extended regimen patches will be applied weekly for 12 consecutive weeks followed by one week patch-free and then another three consecutive weeks of weekly patch applications. In the cyclic regimen patches will be applied for four consecutive cycles where each cycle consists of three weekly patch applications followed by one week patch-free. The total duration of treatment period is 112 days for each regimen.
The invention relates to a traditional Chinese medicinal wine for invigorating spleen and whetting appetite. At present, poor nutrition and poor digestion are widespread for a majority of teenagers and the middle-aged who are physically week. Those people have poor appetite and sleep, and are sallow and emaciated. The invention relates to a traditional Chinese medicinal wine for invigorating spleen and whetting appetite. if those people drink the health-care wine, their spleen and stomach can be greatly adjusted. The traditional Chinese medicinal wine is prepared by steps of: triturating Chinese yam, matrimony vine, chinaroot greenbrier rhizome, bighead atractylodes rhizome, Radix Astragali, Radix Codonopsis, haw and dried orange peel into crude powders, placing the crude powders into a fine sandbag, tying up the top of the sandbag for later use, placing Chinese liquor and the medicines together into a wine pot, covering, and hermetically placing in the shade. After half a month, the traditional Chinese medicinal wine is prepared and can be drunk.